Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Obese Patients
100%
Adjusted Dose
100%
Melphalan
100%
Event-free Survival
50%
Ideal Body Weight
30%
Adjusted Body Weight
30%
Clinical Outcomes
20%
Working Diagnosis
20%
Disease Severity
20%
Multiple Myeloma
20%
Length of Hospital Stay
20%
Patient Demographics
20%
Treatment-related Mortality
20%
High-risk Cytogenetics
20%
Single-center Study
20%
Non-obese
20%
Noninferiority Margin
20%
Non-obese Population
20%
Inclusion Criteria
10%
Transplantation
10%
Adult Patients
10%
Pretransplant
10%
Overall Survival
10%
Marrow Transplantation
10%
Maintenance Therapy
10%
American Society
10%
Am(III)
10%
Jewish
10%
Absence of Evidence
10%
Baseline Characteristics
10%
Dosing Guidelines
10%
Demographic Data
10%
Between-group Difference
10%
Engraftment
10%
Dosage Adjustment
10%
Body Surface Area
10%
Therapy Response
10%
Non-inferiority
10%
Neutrophil Engraftment
10%
Chemotherapy Dose
10%
Actual Weight
10%
Obese Population
10%
Area Calculation
10%
Weight-based Dosing
10%
Lower Confidence Limit
10%
Pharmacokinetic Differences
10%
Conditioning Chemotherapy
10%
Melphalan Conditioning
10%
Non-inferiority Design
10%
Survival Treatment
10%
Data Transplantation
10%
Nursing and Health Professions
Autologous Stem Cell Transplantation
100%
Melphalan
100%
Event Free Survival
55%
Body Weight
44%
Ideal Body Weight
33%
Disease Severity
22%
Length of Stay
22%
Clinical Outcome
22%
Multiple Myeloma
22%
Engraftment
22%
Treatment Response
11%
Overall Survival
11%
Practice Guideline
11%
Patient Population
11%
Maintenance Therapy
11%
Surface Area
11%
Biochemistry, Genetics and Molecular Biology
Autologous Stem Cell Transplantation
100%
Melphalan
100%
Event Free Survival
55%
Body Weight
44%
Ideal Body Weight
33%
Conditioning
22%
Cytogenetics
22%
Overall Survival
11%
Pharmacokinetics
11%
Surface Area
11%
Pharmacology, Toxicology and Pharmaceutical Science
Melphalan
100%
Event Free Survival
55%
Multiple Myeloma
22%
Disease Severity
22%
Overall Survival
11%
Chemotherapy
11%
Pharmacokinetics
11%